Ptc Therapeutics (PTCT) Non-Current Deffered Revenue (2016 - 2020)
Historic Non-Current Deffered Revenue for Ptc Therapeutics (PTCT) over the last 7 years, with Q1 2020 value amounting to $1.8 million.
- Ptc Therapeutics' Non-Current Deffered Revenue fell 8002.94% to $1.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.8 million, marking a year-over-year decrease of 8002.94%. This contributed to the annual value of $3.4 million for FY2019, which is 6487.35% down from last year.
- According to the latest figures from Q1 2020, Ptc Therapeutics' Non-Current Deffered Revenue is $1.8 million, which was down 8002.94% from $3.4 million recorded in Q4 2019.
- In the past 5 years, Ptc Therapeutics' Non-Current Deffered Revenue registered a high of $11.2 million during Q3 2018, and its lowest value of $1.6 million during Q4 2016.
- In the last 5 years, Ptc Therapeutics' Non-Current Deffered Revenue had a median value of $7.2 million in 2017 and averaged $6.4 million.
- As far as peak fluctuations go, Ptc Therapeutics' Non-Current Deffered Revenue soared by 40119.72% in 2017, and later plummeted by 8002.94% in 2020.
- Ptc Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $1.6 million in 2016, then surged by 401.2% to $8.0 million in 2017, then rose by 22.23% to $9.7 million in 2018, then crashed by 64.87% to $3.4 million in 2019, then crashed by 48.23% to $1.8 million in 2020.
- Its Non-Current Deffered Revenue was $1.8 million in Q1 2020, compared to $3.4 million in Q4 2019 and $5.5 million in Q3 2019.